



Stability Indicating RP-HPLC method for simultaneous determination of Aspirin and Omeprazole in the Bulk drug and Synthetic mixture

Nandni Sallam*, Amit Kumar Jain, Shweta Garg and Vaibhav Tiwari

Shri ram Institute of Pharmacy, Jabalpur (M.P.) – India

Article info

Received: 11/02/2023

Revised: 11/03/2023

Accepted: 24/04/2023

© IJPLS

www.ijplsjournal.com

Abstract

In the present research work, a successful attempt was made for “Validated HPLC method development for the estimation of some drugs in marketed formulation” which was developed by experimentation based on thorough literature survey and ascertained by statistical parameters of sampling. The simplicity, rapidity, accurate and reproducibility of the proposed methods completely fulfill the objective of the research work of estimation of the drug in marketed formulation. Proposed method was found to be linear in the range of 5-25 µg/ml aspirin and omeprazole with the correlation coefficient near to one respectively. The validation and the reliability of proposed method were assessed by recovery study. The recovery of added standards (80%, 100%, 120%) was ranging from 100.042±0.260 to 100.033±0.208, 99.944±0.428 and 100.08±0.641, 100.26±0.321 to 98.54±0.553 for aspirin and omeprazole respectively.

Key Words: Estimation, HPLC, Bulk drug

Introduction

Every year many new drugs and newer drug combinations enter the pharmaceutical area. bioanalytical methods for these new and first timer drugs are mostly confined only to the manufacturing company. However, availability of multiple analytical methods for the same drug/drug combinations in their formulations is always advantageous. Moreover, development of such methods helps in training the analysts for skillfully handling the sophisticated analytical instruments and the way for research approach. Reference literature and general survey reveals that similar work of development of bioanalytical methods for new drugs and their combinations introduced in the market is continuously

underway in many academic institutions. The present work is also planned on similar lines.

There are numerous methods for the estimation of Aspirin in fix dosage form. (Gopalakrishnan et al., 2012) worked on analytical method development and validation of HPLC method for the determination of omeprazole in capsule dosage form. Hussein et al., 2016 worked on reversed phase HPLC assay for the determination of omeprazole in human plasma, Reddy et al., (2013) worked on simultaneous determination of aspirin and esomeprazole magnesium in combined tablets by validated ultra performance liquid chromatographic method.

*Corresponding Author

The non-availability of analytical methods till now for the concurrent analysis of single and multi-component formulations made it worthwhile to pursue the present research work. It was also planned to validate the developed methods as per ICH guidelines.

Hence they offer wide area for research activity with relatively minimum chances of exactly repetitive work. The pharmaceutical dosage forms are widely present with multiple active components i.e. in combined dosage forms. This has opened new task for analyst for simultaneous estimation of aspirin and ticagrelor in combined dosage forms. Therefore, in proposed project, to attempt to develop simple, accurate and precise method for analysis of drugs in the blood plasma and validate them.

Experimental

Identification and Characterization of drugs

Solubility

Solubility of all three drugs was observed by dissolving them in different solvents.

Melting point- M.P. of the drug for aspirin and omeprazole 133-135 °C and 156-158 °C respectively found through Melting point apparatus.

Determination of λ_{max} of Drugs

Standard solution (10g/ml) of pure, Aspirin and Omeprazole was prepared. The pure drug solution was scanned on UV spectrophotometer, and λ_{max} determined.




Figure 1: Determination of λ_{max} of Aspirin




Figure 2: Determination of λ_{max} of Omeprazole




Figure 3: Overlain spectra of both the drugs

Preparation of mobile phase

1.75 gm KH_2PO_4 in 1000 ml of water add 1 ml of TEA and adjust the pH – 6 with OPA. Filtered through 0.45 filter paper.

Selection of diluent

Diluent used for preparation of sample were compatible with mobile phase and no any significant affect retention and resolution of analyte. After various trials Acetonitrile was used as diluents.

Preparation of standard stock solution

Accurately weighed 10 mg of aspirin and omeprazole was transferred into 50 ml volumetric flasks separately and dissolved in 10 ml of acetonitrile, then volume was made up to 50 ml with acetonitrile and vortex it to get complete dissolution of drug. Stand it aside for few minute, Concentration of aspirin and omeprazole was 200 $\mu\text{g}/\text{ml}$. (stock-A)

Preparation of Sub Stock Solution 5 ml of solution was taken from stock-A of aspirin transferred into 10 ml volumetric flask separately

and diluted up to 10 ml with diluent (Acetonitrile) to give concentration of 100 µg/ml (Stock-B).

Preparation of Different Solution

0.5ml, 1.0 ml, 1.5ml, 2.0ml and 2.5ml of stock-B was taken separately in 10 ml volumetric flask and volume was made up to 10ml with (Acetonitrile). This gives the solutions of 5µg/ml, 10µg/ml, 15µg/ml, 20µg/ml, 25µg/ml for drug. In same manner 5µg/ml, 10µg/ml, 15µg/ml, 20µg/ml, 25µg/ml of omeprazole also prepared.

Linearity and Calibration Graph

To establish the linearity of analytical method, a series of dilution ranging from 5-25 g/ml was prepared. All the solution were filtered through 0.2m membrane filter and injected, chromatograms were recorded at 275 nm and it was repeat for three times. A calibration graph was plotted between the mean peak area and respective concentration and regression equation was derived.

Table 1: Linearity of aspirin

| Std. Conc. | 5 | 10 | 15 | 20 | 25 |
|------------|---------|----------|----------|----------|----------|
| Rep-1 | 565.589 | 1110.256 | 1565.589 | 2154.589 | 2650.145 |
| Rep-2 | 572.256 | 1125.563 | 1560.254 | 2150.478 | 2645.589 |
| Rep-3 | 583.235 | 1116.658 | 1547.265 | 2165.589 | 2665.458 |
| Mean | 573.693 | 1117.493 | 1557.703 | 2156.885 | 2653.731 |
| S.D. | 8.910 | 7.689 | 9.425 | 7.813 | 10.409 |
| % RSD | 1.553 | 0.688 | 0.605 | 0.362 | 0.392 |




Figure 4: Calibration Curve of aspirin




Figure 5: Chromatogram of aspirin

Table 2: Linearity of Omeprazole

| Std. Conc. | 5 | 10 | 15 | 20 | 25 |
|------------|---------|----------|----------|----------|----------|
| Rep-1 | 825.565 | 1610.254 | 2425.658 | 3250.215 | 4025.658 |
| Rep-2 | 830.254 | 1621.154 | 2430.145 | 3245.897 | 4030.145 |
| Rep-3 | 832.145 | 1632.254 | 2436.658 | 3247.589 | 4032.215 |
| Mean | 829.321 | 1621.221 | 2430.820 | 3247.900 | 4029.339 |
| S.D. | 3.388 | 11.000 | 5.531 | 2.176 | 3.352 |
| % RSD | 0.408 | 0.679 | 0.228 | 0.067 | 0.083 |




Figure 6: Calibration Curve of Omeprazole




Figure 7: Chromatogram of Omeprazole




Figure 8: Chromatogram of aspirin and omeprazole

System Suitability Parameters

Separation variables were set and mobile phase was allowed to saturate the column at 1.00 ml/min. After complete saturation of column, three replicates of working standard of Aspirin 10 µg/ml was injected separately. Peak report and column performance report were recorded for all chromatogram.

Table 3: System suitability parameters of aspirin

| System suitability Parameter | AUC | No. of theoretical plates | Tailing factor |
|------------------------------|----------|---------------------------|----------------|
| Rep-1 | 1250.256 | 3245 | 1.10 |
| Rep-2 | 1252.256 | 3265 | 1.11 |
| Rep-3 | 1245.874 | 3214 | 1.10 |
| Rep-4 | 1242.654 | 3215 | 1.10 |
| Rep-5 | 1242.145 | 3245 | 1.12 |
| Rep-6 | 1244.456 | 3213 | 1.10 |
| Mean | 1246.274 | 3232.833 | 1.11 |
| S.D. | 3.769589 | 21.894 | 0.159 |

Table 4: System suitability parameters of Omeprazole

| System suitability Parameter | AUC | No. of theoretical plates | Tailing factor |
|------------------------------|----------|---------------------------|----------------|
| Rep-1 | 1610.254 | 3050 | 1.32 |
| Rep-2 | 1621.154 | 3045 | 1.35 |
| Rep-3 | 1632.254 | 3045 | 1.21 |
| Rep-4 | 1640.578 | 3047 | 1.45 |
| Rep-5 | 1638.987 | 3050 | 1.65 |
| Rep-6 | 1650.547 | 3056 | 1.54 |
| Mean | 1632.296 | 3048.833 | 1.420 |
| S.D. | 14.536 | 4.167 | 0.159 |

Laboratory Sample Analysis

The In-house tablet formulation of aspirin is available in the strength of 81mg and omeprazole 40mg. Based on this different standard solutions were prepared for quantitative analysis, which gives satisfactory results. Stock solution was prepared in the same manner. Further dilutions were made to prepare the mixed standard of desired concentration.

Table 5: Laboratory sample analyses

| | Label claim | |
|----------------|--------------|-----------------|
| | Aspirin (mg) | Omeprazole (mg) |
| Amount present | 81 | 40 |
| Amount found | 80.98±0.45 | 39.95±0.25 |
| % Assay | 99.98±0.56 | 99.88±0.12 |

Table 6.: Response ration data for linearity of Aspirin

| Replicates | Concentration (g/ml) | Mean AUC | Response Ratio |
|------------|----------------------|----------|----------------|
| Rep-1 | 5 | 573.693 | 114.739 |
| Rep-2 | 10 | 1117.493 | 111.749 |
| Rep-3 | 15 | 1557.703 | 103.847 |
| Rep-4 | 20 | 2156.885 | 107.844 |
| Rep-5 | 25 | 2653.731 | 106.149 |
| SD | | | 4.371 |
| %RSD | | | 4.015 |

Table 7: Response ration data for linearity of Omeprazole

| Replicates | Concentration (g/ml) | Mean AUC | Response Ratio |
|------------|----------------------|----------|----------------|
| Rep-1 | 5 | 829.321 | 165.864 |
| Rep-2 | 10 | 1621.221 | 162.122 |
| Rep-3 | 15 | 2430.820 | 162.055 |
| Rep-4 | 20 | 3247.900 | 162.395 |
| Rep-5 | 25 | 4029.339 | 161.174 |
| SD | | | 1.815 |
| %RSD | | | 1.080 |

Table 6.8: Recovery study of Aspirin

| Level of Recovery (%) | 80 | 100 | 120 |
|---------------------------|------|-------|-------|
| Amount present (mg) | 10 | 10 | 10 |
| | 10 | 10 | 10 |
| | 10 | 10 | 10 |
| Amount of Std. added (mg) | 8 | 10 | 12 |
| | 8 | 10 | 12 |
| | 8 | 10 | 12 |
| Amount recovered (mg) | 7.98 | 9.98 | 11.98 |
| | 8.01 | 10.02 | 11.95 |
| | 8.02 | 10.01 | 12.05 |

| | | | |
|------------------------|---------------|---------------|--------------|
| % Recovery | 99.75 | 99.80 | 99.833 |
| | 100.12 | 100.20 | 99.583 |
| | 100.25 | 100.10 | 100.417 |
| Mean % Recovery | 100.042±0.260 | 100.033±0.208 | 99.944±0.428 |

Table 9: Recovery study of Omeprazole

| Level of Recovery (%) | 80 | 100 | 120 |
|---------------------------|--------------|--------------|--------------|
| Amount present (mg) | 10 | 10 | 10 |
| | 10 | 10 | 10 |
| | 10 | 10 | 10 |
| Amount of Std. added (mg) | 8 | 10 | 12 |
| | 8 | 10 | 12 |
| | 8 | 10 | 12 |
| Amount recovered (mg) | 7.98 | 9.98 | 11.85 |
| | 8.03 | 9.95 | 12.01 |
| | 7.95 | 9.98 | 11.98 |
| % Recovery | 99.75 | 99.80 | 98.75 |
| | 100.38 | 99.50 | 100.08 |
| | 99.38 | 99.80 | 99.83 |
| Mean % Recovery | 99.833±0.505 | 99.700±0.173 | 99.556±0.708 |

Table 10: Results of analysis Data of tablet Formulation

| Drug | Label claim (mg) | Amount Found (%) | Label claim (%) | S.D. |
|------------|------------------|------------------|-----------------|-------|
| Aspirin | 81mg | 80.98 | 99.97 | 0.154 |
| Omeprazole | 40mg | 39.95 | 99.87 | 0.165 |

Table 6.11: Intermediate Precision of Aspirin

| Intra-day Precision | | Inter-day Precision | |
|---------------------|---------------|---------------------|---------------|
| | % Label Claim | | % Label Claim |
| After 1hr | 99.98 | First day | 98.98 |
| After 2hr | 99.81 | Second day | 98.12 |
| After 3hr | 99.55 | Third day | 98.00 |
| After 4hr | 99.45 | | |
| After 5hr | 99.32 | | |

| | | | |
|--------------|--------|--------------|--------|
| After 6hr | 99.05 | | |
| Mean | 99.527 | Mean | 98.367 |
| SD | 0.335 | SD | 0.535 |
| % RSD | 0.337 | % RSD | 0.543 |

Table 6.12: Intermediate Precision of Omeprazole

| Intra-day Precision | | Inter-day Precision | |
|---------------------|---------------|---------------------|---------------|
| | % Label Claim | | % Label Claim |
| After 1hr | 99.12 | First day | 98.00 |
| After 2hr | 99.05 | Second day | 97.98 |
| After 3hr | 99.01 | Third day | 97.50 |
| After 4hr | 98.75 | | |
| After 5hr | 98.21 | | |
| After 6hr | 98.05 | | |
| Mean | 98.698 | Mean | 97.827 |
| SD | 0.460 | SD | 0.283 |
| % RSD | 0.467 | % RSD | 0.289 |

Table 12: LOD and LOQ

| Name | LOD (g/ml) | LOQ (g/ml) |
|-------------------|------------|------------|
| Aspirin | 0.89 | 2.41 |
| Omeprazole | 0.45 | 1.25 |

Conclusion

The simplicity, rapidity, accurate and reproducibility of the proposed methods completely fulfill the objective of the research work of estimation of the drug in marketed formulation. Proposed method was found to be linear in the range of 5-25 µg/ml aspirin and omeprazole with the correlation coefficient near to one respectively. The validation and the reliability of proposed method were assessed by recovery study. The recovery of added standards (80%,100% 120%) was ranging from 100.042±0.260 to 100.033±0.208, 99.944±0.428 and 100.08±0.641, 100.26±0.321 to 98.54±0.553

for aspirin and omeprazole respectively.

Liquid chromatographic system from waters comprising of manual injector, Waters 515 binary pump for constant flow and constant pressure delivery and U.V. detector connected to data ace software controlling the instrumentation as well as processing the data generated were used. The isocratic mobile phase consisted of 1.75 gm KH₂PO₄ in 1000 ml of water add 1 ml of TEA and adjust the pH – 6 with OPA in the ratio of 30:70 v/v at a flow rate of 1.0 ml min⁻¹. A thermo C-18 column (4.6 x 250mm, 5µ particle size) was used as the stationary phase, 275.0 nm was selected as the detection wavelength for UV-vis. detector.

The proposed methods were found to be linear in the range of 5-25 µg/ml with correlation coefficient close to one. Precision was determined by repeatability, Intermediate precision and reproducibility of the drugs. The robustness of developed method was checked by changing in the deliberate variation in solvent. The result obtained shows the developed methods to be Cost effective, Rapid (Short retention time), Simple, Accurate (the value of SD and %RSD less than 2), Precise and can be successfully employed in the routine analysis of these drugs in bulk drug as well as in tablet dosage form.

References

1. R.M. Verma, "Analytical Chemistry (Theory and Practice)", 3rd Edition, PP- 5-10.
2. Dipali Patel, Nishit kumar Patel, Reeta Vaishy, Viral Patel, Chiragsinh Solanki, and Mitul Patel, Development and Validation of RP-HPLC Method for Simultaneous Estimation of Aspirin and Esomeprazole Magnesium in Tablet Dosage Form, Journal of Chemistry Volume 2013, Article ID 751940, 5.
3. PalavaiSripal Reddy, Kishore Kumar Hotha, and ShakilSait, Complexity in Estimation of Esomeprazole and its Related Impurities' Stability in Various Stress Conditions in Low-Dose Aspirin and Esomeprazole Magnesium Capsules, Sci Pharm. 2013 Apr-Jun; 81(2): 475-92.
4. Kalakonda Sri Nataraj, Mohammad BadrudDuza, KalyaniPragallapati, DussaKiran Kumar, Development and validation of RP-HPLC method for the estimation of omeprazole in bulk and capsule dosage forms, International Current Pharmaceutical Journal 2012, 1(11):366-69.
5. Singh Sunil, Choudhary Nisha, Rai Jyoti, Inamullah, Sharma Surabhi, Yadav Ajit Kumar, Gautam Hemendra, Chaturvedi Shashank, Agrawal Vipin Kumar, Validated RP-UPLC Method Development for Estimation of Lansoprazole in Tablet Dosage Form, International Journal of Pharmaceutical Sciences and Drug Research 2013; 5(3):105-7.
6. Sadhana Rajput, SurajFanse, RPHPLC method for Simultaneous Estimation of Lansoprazole and aspirin in Bulk and Laboratory Mixture, Journal of Advanced Pharmacy Education & Research, 2015, 5(2),87-93.
7. S. Gopalakrishnan, K. Jothy and K. Dhanalakshmi, Analytical method development and validation of HPLC method for the determination of omeprazole in capsule dosage form, Elixir Appl. Chem. 52 (2012)11283-86.
8. Rajaa F. Hussein, Nada H. Binhashim, Syed N. Alvi and Muhammad M. Hammami, A validated reversed phase HPLC assay for the determination of omeprazole in human plasma, European journal of pharmaceutical and medical research, 2016, 3(6),26-30.
9. Yarram Rama Koti Reddy, Sudershan Reddy G, M. R. P. Reddy and K. Mukkanti, Rapid simultaneous determination of aspirin and esomeprazole magnesium in combined tablets by validated ultra performance liquid chromatographic method, Journal of Chemical and Pharmaceutical Research, 2013,5(4):181-87.

Cite this article as:

Sallam N., Jain A.K., Garg S. and Tiwari V. (2023). Stability Indicating RP-HPLC method for simultaneous determination of Aspirin and Omeprazole in the Bulk drug and Synthetic mixture. *Int. J. of Pharm. & Life Sci.*, 14(5): 16-23.

Source of Support: Nil

Conflict of Interest: Not declared

For reprints contact: ijplsjournal@gmail.com